PIK3CA
The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.
Relay Therapeutics Licensing FGFR2 Agent to Elevar Therapeutics for $75M
Selling the rights to lirafugratinib will allow Relay to focus on developing its PI3Kα agents.
In the absence of head-to-head studies, oncologists are looking across pivotal trials and are encouraged by Itovebi's safety and efficacy versus Piqray.
Roche Sees Strong Demand for Elevidys Gene Therapy Amid Steady Q3 Pharmaceutical Revenue Growth
Premium
About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.
FDA Approves Genentech's Itovebi Combo for PIK3CA-Mutated Advanced Breast Cancer Patients
In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.
Oct 18, 2023
Celcuity to Raise $50M in Private Placement
Apr 19, 2023
Dec 15, 2020
Dec 15, 2020